



Clearside Biomedical, Inc. to Present at the Deutsche Bank 42nd Annual Health Care Conference

April 26, 2017

ALPHARETTA, Ga., April 26, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its Chief Executive Officer and President, Daniel H. White, will present at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3, 2017 at 4:10 p.m. ET at the InterContinental Hotel in Boston, MA.

A live webcast of the presentation can be accessed on the company's website at www.clearsidebio.com under the "Events & Presentations" tab in the "Investor Relations" section. Following the conference, the presentation webcast will be archived on the website for 30 days.

About Clearside

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and pre-clinical candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.

Contacts:

Stephen Kilmer
Investor Relations
(678) 270-3631
stephen.kilmer@clearsidebio.com

Charles Deignan
Chief Financial Officer
678-270-4005
charlie.deignan@clearsidebio.com



Clearside Biomedical, Inc.